|  |  |  |  |
| --- | --- | --- | --- |
| **eTable 5** Univariable models for disease worsening at two-year follow-up in the total MS population | | | |
|  | **Disease worsening (n=140)** | | |
|  | **OR** | **95 % CI** | **p-value** |
| sNfL ≥ 75 th\* | 1.96 | 0.97-3.95 | 0.060 |
| Age | 1.01 | 0.98-1.05 | 0.405 |
| Total CD3+ | 1.01 | 0.98-1.03 | 0.581 |
| CD3+CD4+ | 1.01 | 0.99-1.04 | 0.441 |
| CD3+CD4+CD25+CD127- (CD4+T-reg) | 1.10 | 0.99-1.23 | 0.067 |
| CD3+CD8+ | 1.002 | 0.96-1.04 | 0.930 |
| CD3+CD8+CD28-CD127- (CD8+T-reg) | 0.99 | 0.97-1.01 | 0.154 |
| CD3+CD4+CCR6-CD161-CXCR3+ (Th1) | **1.05** | **1.00-1.11** | **0.048** |
| CD3+CD4+CCR6+CD161+CXCR3-CCR4+ (Th17) | 1.24 | 0.79-1.95 | 0.357 |
| CD3+CD4+CCR6+CD161+CxCR3highCCR4low (Th1/Th17) | 1.14 | 0.90-1.44 | 0.272 |
| Total CD19+ | 0.98 | 0.92-1.04 | 0.437 |
| CD19+CD24highCD38low (B-memory) | 0.98 | 0.94-1.02 | 0.269 |
| CD19+CD24lowCD38low (B-mature) | 1.002 | 0.98-1.02 | 0.869 |
| CD19+CD24highCD38high (B-reg) | 1.02 | 0.99-1.05 | 0.292 |
| CD19+CD24-CD38high (plasma B-cells) | 1.04 | 0.98-1.11 | 0.165 |
| CD16+CD56low (CD56dim NK cells) | 0.99 | 0.97-1.01 | 0.180 |
| CD16+CD56high (CD56bright NK cells) | 0.99 | 0.89-1.09 | 0.832 |
| Abbreviations: sNfL= serum neurofilament light chain; disease worsening = ≥ 3 new cerebral MRI lesions and/or confirmed Expanded Disability Status Score (EDSS) progression and/or evidence of a new clinical relapse. Results are presented with odds ratio (OR), 95% confidence interval (CI) and p-value. The analyses were adjusted for age, gender and treatment level (no treatment, active treatment and highly active treatment).\*Cut off 75th percentile: 20-29 years ≥ 4.325 pg/ml, 30-34 years ≥ 6.60 pg/ml, 35-39 years ≥ 7.05 pg/ml, 40-44 years ≥ 6.825 pg/ml, 45-49 years ≥ 7.075 pg/ml, 50-54 years ≥ 8.225 pg/ml, 55-59 years ≥ 11.15 pg/ml, 60-69 years ≥ 12.95 pg/ml. | | | |